4//SEC Filing
Litchfield Caroline 4
Accession 0001127602-22-013030
CIK 0000310158other
Filed
May 2, 8:00 PM ET
Accepted
May 3, 4:22 PM ET
Size
9.2 KB
Accession
0001127602-22-013030
Insider Transaction Report
Form 4
Litchfield Caroline
EVP & CFO
Transactions
- Exercise/Conversion
Common Stock
2022-05-01$88.69/sh+866$76,806→ 27,453.288 total - Tax Payment
Common Stock
2022-05-01$88.69/sh−427$37,871→ 27,026.288 total - Exercise/Conversion
Restricted Stock Unit
2022-05-01−866→ 866 totalFrom: 2021-05-01Exp: 2023-05-01→ Common Stock (866 underlying)
Footnotes (4)
- [F1]Holdings include shares acquired in dividend reinvestment transactions.
- [F2]Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
- [F3]Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
- [F4]These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
Documents
Issuer
Merck & Co., Inc.
CIK 0000310158
Entity typeother
Related Parties
1- filerCIK 0001854928
Filing Metadata
- Form type
- 4
- Filed
- May 2, 8:00 PM ET
- Accepted
- May 3, 4:22 PM ET
- Size
- 9.2 KB